Mar. 19 at 3:27 PM
$IFRX Been working on an INF904-LN thesis (lupus nephritis) to round out what I think are the top 3 nephrology indications, this area of study explicitly mentioned on the InflaRx pipeline, along with mention of it recently at Oppenheimer.
I keep seeing the same biology: “Complement activation is a central pathogenic mechanism in MN, predominantly through the classical pathway, with contributions from the mannose-binding lectin and alternative pathways…with urinary levels of complement activation products (Ba, C5a, and membrane attack complex) strongly correlating with disease severity.”
This quote specific to membranous nephropathy (MN), though also the case in IgAN, DKD, and LN: C5a in the urine, complement activation in kidney tissue. Different from systemic C5a levels which fluctuate. Makes for a very interesting biomarker moving forward, perhaps one day an alternative to typical kidney biopsy, on often done-too-late procedure, kidney damage well underway by then.
